You are here: Home » Companies » News
Business Standard

Glenmark Pharma gets USFDA nod for generic skin inflammation treatment foam

The company said its current portfolio consists of 150 products authorised for distribution in the US and 52 ANDA's pending approval with the USFDA

Topics
Glenmark Pharmaceuticals  |  Usfda  |  Glenmark Pharma

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals

Monday said it has received final approval from the US health regulator for its generic version of clobetasol propionate foam, a steroid used to treat inflammation and itching of the skin.

The approval has been granted by the United States Food and Drug Administration (USFDA) to Glenmark Pharmaceuticals, US, for clobetasol propionate foam, 0.05 per cent, a generic version of Olux Foam, 0.05 per cent, of Mylan Pharmaceuticals, the company said in a statement.

Citing IQVIA sales data, Glenmark said, Olux foam 0.05 per cent achieved annual sales of approximately $50.9 million in the 12-month period ended December 2018.

The company said its current portfolio consists of 150 products authorised for distribution in the US and 52 ANDA's pending approval with the

Shares of were trading at Rs 569 apiece, down 0.11 per cent from their previous close, on BSE.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 18 2019. 12:40 IST
RECOMMENDED FOR YOU
.